Literature DB >> 3919133

Distribution of apolipoprotein A-IV in human plasma.

C L Bisgaier, O P Sachdev, L Megna, R M Glickman.   

Abstract

Human apoA-IV was purified from delipidated urinary chylomicrons. Monospecific antibodies were raised in rabbits and used to develop a double antibody radioimmunoassay (RIA). Displacement of 125I-labeled apoA-IV by plasma or purified chylomicron apoA-IV resulted in parallel displacement curves, indicating that apoA-IV from both sources share common antigenic determinants. The apoA-IV level in plasma from normal healthy fasting male subjects (n = 5) was 37.4 +/- 4.0 mg/dl, while fat-feeding increased the level to 49.1 +/- 7.9 mg/dl (P less than 0.05) at 4 hr. The apoA-IV level in plasma from abetalipoproteinemic fasting subjects was 13.7 +/- 3.1 mg/dl (n = 5). Plasma from a single fasting Tangier subject showed a reduced apoA-IV level of 21.1 mg/dl. The distribution of apoA-IV in fasting and postprandial plasma was determined by 6% agarose gel chromatography. Fifteen to 25% of plasma apoA-IV eluted in the region of plasma high density lipoprotein (HDL), with the remainder eluting in subsequent column fractions. In abetalipoproteinemic plasma this HDL fraction is reduced and lacks apoA-IV, suggesting that at least some of the apoA-IV on these particles is normally derived from triglyceride-rich lipoproteins. Lipemic plasma from a fat-fed subject showed a small rise (3%) in chylomicron-associated apoA-IV. Gel-filtered HDL and subsequent apoA-IV-containing fractions were subjected to 4-30% polyacrylamide gradient gel electrophoresis (4/30 GGE), and apoA-IV was identified by immunolocalization following transfer of proteins to nitrocellulose paper. In normal plasma apoA-IV was localized throughout all HDL fractions. In addition, normal plasma contained apoA-IV localized in a small particle (diameter 7.8-8.0 nm). This particle also contained apoA-I and lipid. A markedly elevated saturated to unsaturated cholesteryl ester ratio was present in gel-filtered plasma fractions containing small HDL, suggesting an intracellular origin of these particles. In abetalipoproteinemic plasma apoA-IV was absent from all HDL fractions except for the small HDL particles, suggesting that they are not derived from the surface of triglyceride-rich particles. All plasmas contained free apoA-IV. In contrast to gel-filtered plasma, lipoprotein subfractions of fasted normal plasma prepared in the ultracentrifuge primarily contained apoA-IV in the d greater than 1.26 g/ml fraction, suggesting an artifactual redistribution of the apolipoprotein during centrifugation. Overall, these data suggest that apoA-IV secretion into plasma is increased with fat feeding, and that apoA-IV normally exists as both a free apolipoprotein and in association with HDL particles.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3919133

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  28 in total

1.  The effects of scale: variation in the APOA1/C3/A4/A5 gene cluster.

Authors:  Stephanie M Fullerton; Anne V Buchanan; Vibhor A Sonpar; Scott L Taylor; Joshua D Smith; Christopher S Carlson; Veikko Salomaa; Jari H Stengård; Eric Boerwinkle; Andrew G Clark; Deborah A Nickerson; Kenneth M Weiss
Journal:  Hum Genet       Date:  2004-04-24       Impact factor: 4.132

2.  Distribution of specific apolipoproteins determined by immunoblotting of baboon lipoproteins resolved by polyacrylamide gradient gel electrophoresis.

Authors:  D L Rainwater; C M Kammerer; M L Cheng; M L Sparks; J L VandeBerg
Journal:  Biochem Genet       Date:  1992-04       Impact factor: 1.890

3.  Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.

Authors:  H N Ginsberg; N A Le; I J Goldberg; J C Gibson; A Rubinstein; P Wang-Iverson; R Norum; W V Brown
Journal:  J Clin Invest       Date:  1986-11       Impact factor: 14.808

4.  Structure, evolution, and polymorphisms of the human apolipoprotein A4 gene (APOA4).

Authors:  S K Karathanasis; P Oettgen; I A Haddad; S E Antonarakis
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

5.  Genetic ablation of apolipoprotein A-IV accelerates Alzheimer's disease pathogenesis in a mouse model.

Authors:  Yujie Cui; Mingwei Huang; Yingbo He; Shuyan Zhang; Yongzhang Luo
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

6.  Selective evaluation of high density lipoprotein from mouse small intestine by an in situ perfusion technique.

Authors:  Satoshi Yamaguchi; Bo Zhang; Takeshi Tomonaga; Utako Seino; Akiko Kanagawa; Masaru Segawa; Hironori Nagasaka; Akira Suzuki; Takashi Miida; Sohsuke Yamada; Yasuyuki Sasaguri; Takefumi Doi; Keijiro Saku; Mitsuyo Okazaki; Yoshihiro Tochino; Ken-Ichi Hirano
Journal:  J Lipid Res       Date:  2014-02-25       Impact factor: 5.922

7.  A comparison of the mouse and human lipoproteome: suitability of the mouse model for studies of human lipoproteins.

Authors:  Scott M Gordon; Hailong Li; Xiaoting Zhu; Amy S Shah; L Jason Lu; W Sean Davidson
Journal:  J Proteome Res       Date:  2015-04-27       Impact factor: 4.466

8.  The two-receptor model of lipoprotein clearance: tests of the hypothesis in "knockout" mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins.

Authors:  S Ishibashi; J Herz; N Maeda; J L Goldstein; M S Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

9.  Intestinal expression of human apolipoprotein A-IV in transgenic mice fails to influence dietary lipid absorption or feeding behavior.

Authors:  K Aalto-Setälä; C L Bisgaier; A Ho; K A Kieft; M G Traber; H J Kayden; R Ramakrishnan; A Walsh; A D Essenburg; J L Breslow
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

10.  Apolipoprotein M expression increases the size of nascent pre beta HDL formed by ATP binding cassette transporter A1.

Authors:  Anny Mulya; Jeongmin Seo; Amanda L Brown; Abraham K Gebre; Elena Boudyguina; Gregory S Shelness; John S Parks
Journal:  J Lipid Res       Date:  2009-09-18       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.